Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
Review on Lutetium-177 vipivotide tetraxetan in Prostate cancer, in Journal not given (2023), one of the most cited Europe PMC records with Lutetium-177 vipivotide tetraxetan in its title.
Overview
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 40209019. Its title names Lutetium-177 vipivotide tetraxetan and its text names Prostate cancer; PubMed types it as a review (Review). It was matched automatically to the idea "Alpha-emitting PSMA therapy at first metastatic diagnosis" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Matched by Lutetium-177 vipivotide tetraxetan in the title and Prostate cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- A review summarises other studies; the primary reports it cites are the evidence.
Similar pages
not linked directly; found by shared links- Key paperSequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.
- TrialPSMAddition
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.
- TermDosimetry
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.
- TreatmentLutetium-177 vipivotide tetraxetan
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.